TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31912787

Group type: EXPERIMENTAL
Intervention: Frozen gloves (FGs) worn on both hands during chemotherapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (not wearing FGs)
Number of subjects: 180
Study: 29532440

Group type: EXPERIMENTAL
Intervention: ADS-5102 (amantadine) extended-release capsules, administered orally once daily at bedtime.
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 27626255

Group type: EXPERIMENTAL
Intervention: Thrombovasim® 1,600 IU
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Thrombovasim® 3,200 IU
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Thrombovasim® 4,800 IU
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 24310580

Group type: COMPARATOR
Intervention: Conventional liposuction with abdominoplasty
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mixture of conventional and laser-assisted liposuction with abdominoplasty
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Laser-assisted liposuction with abdominoplasty
Number of subjects: 36
Study: 22720764

Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) intervention
Number of subjects: 928

Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 928
Study: 19948568

Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM) intervention
Number of subjects: 48

Group type: COMPARATOR
Intervention: Community intervention (control)
Number of subjects: 48
Study: 19091759

Group type: EXPERIMENTAL
Intervention: Invitations timed in the week of their birthday or assigned to screening in the first or second week after their birthday
Number of subjects: 12960

Group type: EXPERIMENTAL
Intervention: Invitations timed in December
Number of subjects: 12960

Group type: EXPERIMENTAL
Intervention: Overall attendance improvement
Number of subjects: 12960
Study: 15823447

Group type: EXPERIMENTAL
Intervention: tiotropium 18 microg + formoterol 12 microg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: formoterol 12 microg + tiotropium 18 microg
Number of subjects: 20
Study: 12433894

Group type: EXPERIMENTAL
Intervention: Conventional angioplasty with optional stenting
Number of subjects: 181
Study: 10608394

Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg MultiHance
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.2 mmol/kg MultiHance
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg and 0.2 mmol/kg MultiHance
Number of subjects: 120
Study: 7795829

Group type: EXPERIMENTAL
Intervention: Ideal diet (high in fruits, vegetables, whole cereal products, low-fat dairy, fish, chicken, and lean meats)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Fruits and vegetables diet (high in potassium, magnesium, and dietary fiber)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Control dietary pattern (low in potassium, magnesium, calcium, and fiber)
Number of subjects: 456
Study: 2393206

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg four times daily for 2 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 13
Study: 7032370

Group type: EXPERIMENTAL
Intervention: Flunisolide nasal solution (300 micrograms/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31846189

Group type: EXPERIMENTAL
Intervention: RJ101
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 31204294

Group type: EXPERIMENTAL
Intervention: Self-dosed heavy-slow resistance training program
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pre-determined heavy-slow resistance training program
Number of subjects: 70
Study: 28068956

Group type: COMPARATOR
Intervention: Beta-lactam monotherapy
Number of subjects: 2283

Group type: EXPERIMENTAL
Intervention: Beta-lactam/macrolide combination
Number of subjects: 2283

Group type: EXPERIMENTAL
Intervention: Fluoroquinolone monotherapy
Number of subjects: 2283
Study: 25788197

Group type: COMPARATOR
Intervention: LAM 100 mg daily
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: ADF 10 mg daily
Number of subjects: 70
Study: 23098358

Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy practice (task-oriented approach)
Number of subjects: 46
Study: 21414565

Group type: EXPERIMENTAL
Intervention: aliskiren/amlodipine/HCTZ (300/10/25 mg)
Number of subjects: 412

Group type: COMPARATOR
Intervention: aliskiren/amlodipine (300/10 mg)
Number of subjects: 412
Study: 19153265

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Combination of Aliskiren and Losartan
Number of subjects: 465
Study: 17397702

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal electroanalgesia (TSE)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (sham TSE)
Number of subjects: 41
Study: 15226274

Group type: EXPERIMENTAL
Intervention: Sokolow‐Lyon product criterion
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Cornell criterion
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Cornell product criteria
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: ECG LVH criteria
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Cornell and Cornell product criteria
Number of subjects: 348
Study: 10968732

Group type: COMPARATOR
Intervention: Control diet (1,200 to 1,500 kcal/d) - Group A
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Isoenergetic diet with meal and snack replacements - Group B
Number of subjects: 100
Study: 9063541

Group type: EXPERIMENTAL
Intervention: Powdered HSA charcoal (2,000 m2/g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Granular HSA charcoal
Number of subjects: 6

Group type: COMPARATOR
Intervention: Low-surface-area (LSA) charcoal (950 m2/g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Total AUC for the 5-hour study period with powdered HSA charcoal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Total AUC for the 5-hour study period with granular HSA charcoal
Number of subjects: 6
Study: 8095006

Group type: EXPERIMENTAL
Intervention: Glucagon infusion at 3 ng min-1kg-1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Glucagon infusion at 6 ng min-1kg-1
Number of subjects: 18

Group type: COMPARATOR
Intervention: Octreotide pretreatment (0.8 microgram/kg subcutaneously) before insulin infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Insulin infusion during hypoglycaemia
Number of subjects: 18
Study: 3757767

Group type: EXPERIMENTAL
Intervention: Contingent methadone delivery (N = 13)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Non-contingent methadone delivery (N = 13)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (N = 13)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Contingent methadone delivery
Number of subjects: 39
Study: 31615489

Group type: EXPERIMENTAL
Intervention: Peer evaluation system (intervention group)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Standard team project approach (control group)
Number of subjects: 223
Study: 29148074

Group type: EXPERIMENTAL
Intervention: Salutogenic Healthy Ageing Programme Embracement (SHAPE)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 154
Study: 26757788

Group type: EXPERIMENTAL
Intervention: LY3015014 300 mg every 4 weeks (Q4W)
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: LY3015014 300 mg every 8 weeks (Q8W)
Number of subjects: 527

Group type: COMPARATOR
Intervention: Placebo Q4W
Number of subjects: 527
Study: 24119318

Group type: EXPERIMENTAL
Intervention: 12-week lifestyle intervention consisting of aerobic and resistance exercise with parallel dietary advice
Number of subjects: 100

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 100
Study: 22453654

Group type: EXPERIMENTAL
Intervention: Nurse-led care
Number of subjects: 712

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 712
Study: 20500784

Group type: EXPERIMENTAL
Intervention: 1-year group leisure programme
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 37
Study: 17466520

Group type: EXPERIMENTAL
Intervention: Rigid spinal orthosis
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: SpineCor (flexible spinal orthosis)
Number of subjects: 21
Study: 15866953

Group type: EXPERIMENTAL
Intervention: Teno Fix
Number of subjects: 67

Group type: COMPARATOR
Intervention: Suture repair (control)
Number of subjects: 67
Study: 12648985

Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation (EBL)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Drug therapy with propranolol (with or without isosorbide‐5‐mononitrate [ISMN])
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Propranolol with ISMN for non-responders
Number of subjects: 136
Study: 10848909

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 120 mg
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 688

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 688
Study: 8812029

Group type: EXPERIMENTAL
Intervention: Spatially random configurations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Linear arrays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dense arrangement of items
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Differentiating objects by color
Number of subjects: 0
Study: 1582601

Group type: EXPERIMENTAL
Intervention: Nicardipine 3 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ceruletide 5 ng/kg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 2933261

Group type: EXPERIMENTAL
Intervention: BAY m1099 (1-deoxynojirimycin derivative)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30982943

Group type: EXPERIMENTAL
Intervention: INSPIRE intervention (integrated Body Project and Healthy Weight Intervention)
Number of subjects: 27
Study: 31046722

Group type: EXPERIMENTAL
Intervention: PowerPoint‐oriented health education intervention
Number of subjects: 1675

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1675
Study: 28146243

Group type: EXPERIMENTAL
Intervention: R-E group (smoking-related memory retrieval followed by extinction training)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: R-E group
Number of subjects: 88

Group type: COMPARATOR
Intervention: NR-E group (nonsmoking-related retrieval followed by extinction training)
Number of subjects: 88
Study: 24510801

Group type: EXPERIMENTAL
Intervention: Patterned electrical stimulation applied to the S2 or S3 dermatome
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no stimulation)
Number of subjects: 10
Study: 23036478

Group type: EXPERIMENTAL
Intervention: AG200-15 patch (highest dose)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Lowest-dose patch
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: All three patches
Number of subjects: 116
Study: 20182454

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS with RAS blockade
Number of subjects: 7665

Group type: COMPARATOR
Intervention: Nifedipine GITS
Number of subjects: 7665
Study: 19916825

Group type: EXPERIMENTAL
Intervention: Community-based exercise program led by fitness instructors
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Community-based exercise program
Number of subjects: 4
Study: 16491144

Group type: EXPERIMENTAL
Intervention: Lateral condensation
Number of subjects: 290

Group type: COMPARATOR
Intervention: Vertical compaction
Number of subjects: 290
Study: 15328674

Group type: EXPERIMENTAL
Intervention: Educational handout monthly for 2 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One-on-one educational session with a physician or nurse practitioner
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 0
Study: 11732287

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9150029

Group type: EXPERIMENTAL
Intervention: Reciprocating-gait orthoses (RGOs)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hip-knee-ankle-foot orthoses (HKAFOs)
Number of subjects: 8
Study: 7910836

Group type: EXPERIMENTAL
Intervention: Inactivated HIV-1 immunogen in incomplete Freund's adjuvant (IFA)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Adjuvant alone (Control)
Number of subjects: 103
Study: 3109017

Group type: EXPERIMENTAL
Intervention: Enprostil, 35 micrograms twice daily
Number of subjects: 106

Group type: COMPARATOR
Intervention: Cimetidine, 400 mg twice daily
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Enprostil (nonsmokers)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Cimetidine (nonsmokers)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Enprostil (smokers)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Cimetidine (smokers)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Enprostil
Number of subjects: 106

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 106
Study: 1972218

Group type: EXPERIMENTAL
Intervention: 100 mg oral nicotinamide daily for three weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo daily for three weeks
Number of subjects: 29
Study: 31274492

Group type: EXPERIMENTAL
Intervention: Phrenic Nerve Infiltration with 10 mL of 0.2% Ropivacaine
Number of subjects: 126

Group type: COMPARATOR
Intervention: Paracetamol Infusion with 20mg/kg
Number of subjects: 126
Study: 28033193

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Iliac cancellous bone and marrow grafts without PRP (Control)
Number of subjects: 29
Study: 25873635

Group type: EXPERIMENTAL
Intervention: Tabalumab 120 mg every four weeks (120/Q4W)
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Tabalumab 90 mg every two weeks (90/Q2W)
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Tabalumab groups
Number of subjects: 1041
Study: 23567397

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (50-300 mg/day, flexible dosing)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 338
Study: 21564464

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 18

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 18
Study: 19450647

Group type: EXPERIMENTAL
Intervention: DCs infected with CP-HIV+KLH (arm A, n=14)
Number of subjects: 29
Study: 17006279

Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza vaccine, trivalent (CAIV-T)
Number of subjects: 2187

Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 2187
Study: 14556922

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 1021
Study: 11543984

Group type: EXPERIMENTAL
Intervention: Low dose Delta(9)-tetrahydrocannabinol (THC) with ethanol (0.35 g/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate dose Delta(9)-tetrahydrocannabinol (THC) with ethanol (0.7 g/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo THC with ethanol (placebo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo THC with placebo ethanol
Number of subjects: 0
Study: 9631978

Group type: EXPERIMENTAL
Intervention: Low-dose combination of bisoprolol/hydrochlorothiazide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study: 8161715

Group type: COMPARATOR
Intervention: Dilapress 120 mg tablets (twice-daily dosing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dilapress 240 mg tablets (once-daily treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cardizem CD
Number of subjects: 0
Study: 3360860

Group type: EXPERIMENTAL
Intervention: Teonova (theophylline) 600 mg administered 10 min before breakfast
Number of subjects: 20

Group type: COMPARATOR
Intervention: Teonova (theophylline) 600 mg administered 60 min after breakfast
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Teonova (theophylline) 600 mg administered 10 min before dinner
Number of subjects: 20

Group type: COMPARATOR
Intervention: Teonova (theophylline) 600 mg administered 60 min after dinner
Number of subjects: 20
Study: 29546346

Group type: EXPERIMENTAL
Intervention: Afebrile P. falciparum infections detected with RDTs
Number of subjects: 32
Study: 26698689

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 855
Study: 24512252

Group type: EXPERIMENTAL
Intervention: 17P (250mg weekly injections)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 23738949

Group type: EXPERIMENTAL
Intervention: Gait analysis report
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no gait analysis report)
Number of subjects: 39
Study: 20047620

Group type: EXPERIMENTAL
Intervention: Colestilan
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 18713550

Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscope (GSVL)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope (MDL)
Number of subjects: 76
Study: 16410271

Group type: EXPERIMENTAL
Intervention: Clamping of the dialysate outlet line
Number of subjects: 20

Group type: COMPARATOR
Intervention: No clamping of the dialysate outlet line
Number of subjects: 20
Study: 12562449

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily for 4 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 11163746

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-infarction care
Number of subjects: 0
Study: 9159565

Group type: COMPARATOR
Intervention: Angiotensin II (Ang II) infusion
Number of subjects: 10
Study: 8203983

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 75
Study: 3307889

Group type: EXPERIMENTAL
Intervention: Grenz ray therapy (3 Gy applied on six occasions at intervals of 1 week)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Simulated therapy (control)
Number of subjects: 24
Study: 31072186

Group type: EXPERIMENTAL
Intervention: Trium CTG Online® computer analysis
Number of subjects: 26

Group type: COMPARATOR
Intervention: Obstetricians' interpretation
Number of subjects: 26
Study: 30765433

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 291
Study: 28215661

Group type: EXPERIMENTAL
Intervention: Tailored help-seeking advice (screening group)
Number of subjects: 10190

Group type: COMPARATOR
Intervention: General mental health advice (control group)
Number of subjects: 10190
Study: 26080572

Group type: EXPERIMENTAL
Intervention: Qinghouyan lozenge for 5 days
Number of subjects: 144

Group type: COMPARATOR
Intervention: Qinghouyan oral Liquid for 5 days
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Qinghouyan lozenge
Number of subjects: 144

Group type: COMPARATOR
Intervention: Qinghouyan oral Liquid
Number of subjects: 144
Study: 23850914

Group type: EXPERIMENTAL
Intervention: Age group 20 to 39 years
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Age group 40 to 49 years
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Age group 50 to 59 years
Number of subjects: 5

Group type: COMPARATOR
Intervention: Age group 60 to 69 years
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Age group ≥70 years
Number of subjects: 5

Group type: COMPARATOR
Intervention: Youngest group (20 to 39 years) vs. referent group (60 to 69 years)
Number of subjects: 5
Study: 21388992

Group type: EXPERIMENTAL
Intervention: Rolofylline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 19553405

Group type: EXPERIMENTAL
Intervention: Cranberry juice (CJ) 240 mL once daily for 2 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo beverage 240 mL once daily for 2 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cranberry juice (CJ)
Number of subjects: 30
Study: 17201539

Group type: EXPERIMENTAL
Intervention: Explicit contemplation of cancer
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Thinking about cancer under high cognitive load
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Subliminal primes of the word cancer
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High perceived vulnerability to cancer
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High cognitive load after cancer salience
Number of subjects: 5
Study: 15113993

Group type: EXPERIMENTAL
Intervention: Home-based exercise supplemented with an 8-week class-based exercise programme
Number of subjects: 214

Group type: COMPARATOR
Intervention: Home-based exercise alone
Number of subjects: 214
Study: 11133601

Group type: EXPERIMENTAL
Intervention: Combination of 0.75 mg/kg preservative‐free S(+)‐ketamine and 0.75 mg/kg midazolam
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg midazolam
Number of subjects: 62

Group type: COMPARATOR
Intervention: 1.5 mg/kg preservative‐free S(+)‐ketamine
Number of subjects: 62
Study: 9695971

Group type: EXPERIMENTAL
Intervention: 5.0 microg/kg/d MGDF
Number of subjects: 8

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus 5.0 microg/kg/d MGDF
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus MGDF
Number of subjects: 8
Study: 8205826

Group type: EXPERIMENTAL
Intervention: Continuous enteral feeding
Number of subjects: 95

Group type: COMPARATOR
Intervention: Topical antimicrobial prophylaxis and sucralfate (1 g/6 hrs)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Gastric pH-increasing stress ulcer prophylaxis
Number of subjects: 95

Group type: COMPARATOR
Intervention: No enteral feeding
Number of subjects: 95
Study: 2530922

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 26
Study: 1097878

Group type: EXPERIMENTAL
Intervention: NAB 365 (3 X 10 and 20 mug)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Salbutamol (3 X 2.0 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Terbutalin (3 X 2.5 mg)
Number of subjects: 96